Article
Pharmacology & Pharmacy
Luca Casula, Francesco Lai, Elena Pini, Donatella Valenti, Chiara Sinico, Maria Cristina Cardia, Salvatore Marceddu, Giorgia Ailuno, Anna Maria Fadda
Summary: Curcumin, when formulated as nanosuspensions, shows potential as an effective component in asthma treatment. The optimized Curcumin nanosuspension exhibited improved stability and solubility, while the multicomponent formulation also showed good stability and particle size distribution over 90 days. Nebulization tests of the samples demonstrated optimal aerodynamic parameters and mass median aerodynamic diameter below 5 μm.
Article
Respiratory System
Alberto Papi, Diogenes S. Ferreira, Ioana Agache, Eugenio Baraldi, Richard Beasley, Guy Brusselle, Courtney Coleman, Mina Gaga, Carolina Maria Gotera Rivera, Erik Melen, Ian D. Pavord, Deborah Penate Gomez, Daniel Schuermans, Antonio Spanevello, Thomy Tonia, Florence Schleich
Summary: Recent clinical trials have shown that using as-needed ICS/formoterol could be a potential treatment option for mild asthma. The European Respiratory Society's Task Force has provided evidence-based recommendations, suggesting that adults with mild asthma should use as-needed ICS/formoterol instead of regular ICS maintenance treatment plus as-needed SABA, while adolescents can choose either as-needed ICS/formoterol or ICS maintenance treatment plus as-needed SABA.
EUROPEAN RESPIRATORY JOURNAL
(2023)
Review
Respiratory System
Ashfaq Hasan, Priyanka Mukherjee, Sushmeeta Chhowala, Meena Lopez, Prashant N. Chhajed
Summary: The advancement in drug formulation has led to a new generation of inhalers that can generate aerosols with extrafine drug particles for better penetration into the lung periphery. The introduction of extrafine beclomethasone/formoterol (BDP-FF) has provided enhanced lung deposition capabilities. Studies have shown that extrafine BDP-FF demonstrates good efficacy and effectiveness in asthma and COPD.
Article
Cardiac & Cardiovascular Systems
A. Renner, K. Marth, R. Breyer-Kohansal, W. Pohl
Summary: Five non-interventional studies from Austria evaluated the real-world effectiveness and tolerability of an extrafine fixed dose beclomethasone/formoterol treatment for partially or non-controlled asthma patients. The treatment showed significant improvements in asthma control, lung function, and symptom scores, with high tolerability and patient satisfaction.
RESPIRATORY MEDICINE
(2023)
Review
Health Care Sciences & Services
Alfredo Chetta, Nicola Facciolongo, Cosimo Franco, Laura Franzini, Alessio Piraino, Carmelina Rossi
Summary: In recent years, there has been a shift in the management perspective of respiratory diseases due to increasing evidence of the significant role of small airways in obstructive airflow. This evidence has led to a redefinition of disease severity, identification of small airways disease phenotypes and early signs, and revisions to prevalence and overall epidemiological data. Efforts have focused on assessing small airways involvement and early detection, including clinical trials evaluating the use of extra-fine formulations to target small airways in uncontrolled asthma and severe COPD.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT
(2022)
Letter
Pharmacology & Pharmacy
Silvano Dragonieri, Vitaliano Nicola Quaranta, Andrea Portacci, Giovanna Elisiana Carpagnano
Summary: Inhaled corticosteroids are essential in asthma treatment, while the use of monoclonal antibodies has had a significant impact in patients with severe asthma. However, the high cost of monoclonal antibodies necessitates a careful cost-benefit evaluation. The use of single-inhaler Beclometasone Dipropionate/For-moterol Fumarate/Glycopyrronium can improve the performance of severe asthma patients and delay the use of costly monoclonal antibodies, thus reducing healthcare costs.
PULMONARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Engineering, Environmental
Wei-Hsin Chen, Che-Ming Chang, Justus Kavita Mutuku, Su Shiung Lam, Wen-Jhy Lee
Summary: By predicting the deposition fractions of aerosols in healthy and asthmatic human airways using numerical methods, this study reveals that the curved and sinuous folds in asthmatic airways lead to the formation of complex secondary flows and higher deposition fractions, compared to healthy airways. This information is crucial for understanding the effects of aerosol particle sizes on asthma treatment and for preventing exacerbation of chronic ailments like asthma and epidemics like COVID-19.
JOURNAL OF HAZARDOUS MATERIALS
(2021)
Article
Respiratory System
Roberta Pisi, Marina Aiello, Alessio Piraino, Davide Paleari, Annalisa Frizzelli, Giuseppina Bertorelli, Alfredo Chetta
Summary: In this study, treatment with BDP/FF extra-fine formulation improved functional parameters related to small airway disease and the disease impact on health status in COPD patients.
Article
Respiratory System
Paul M. O'Byrne, Helen K. Reddel, Richard Beasley
Summary: ICS-containing reliever medication is superior to SABA as reliever alone and equivalent to maintenance ICS and SABA as reliever, particularly in reducing risks of severe asthma exacerbations, in studies comparing these reliever options.
EUROPEAN RESPIRATORY JOURNAL
(2021)
Article
Pharmacology & Pharmacy
G. H. Spasov, R. Rossi, A. Vanossi, C. Cottini, A. Benassi
Summary: Recent advances in human respiratory system characterization and multi-phase flow dynamics have made numerical simulations important for studying aerosol deposition in the lungs. However, the development of an efficient numerical and mathematical description is still a challenge, as identifying critical aspects of the modeling and determining which details are irrelevant is difficult.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2022)
Review
Cardiac & Cardiovascular Systems
Alvar Agusti, Neil Barnes, Alvaro A. Cruz, Peter G. Gibson, Liam G. Heaney, Hiromasa Inoue, David Leather, Fernando J. Martinez, Vanessa M. McDonald, John Oppenheimer, Alberto Papi, Ian D. Pavord, Mike Thomas, Samantha Walker, Louisa Yates
Summary: Asthma and COPD are prevalent chronic airways diseases that require a personalized and precise management approach. The management strategy based on Treatable Traits shows promise in improving outcomes for patients with chronic airway diseases, but further research is needed to guide implementation.
RESPIRATORY MEDICINE
(2021)
Article
Medicine, General & Internal
Ibrahim Bukhari, Muhammad Ashfaq, Bader-U-Nisa, Aijaz Ahmed, Hira Waseem, Mehrunnisa Yasir
Summary: The study compared the mean change in peak expiratory flow values in children with mild persistent asthma receiving inhaled beclomethasone dipropionate versus inhaled budesonide, and found that budesonide had slightly better efficacy compared to beclomethasone dipropionate.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Review
Respiratory System
Mike Thomas, Richard Beasley
Summary: The treatable traits approach is a personalized management method for asthma and chronic obstructive airways disease (COPD), based on recognizing the heterogeneous nature of these conditions and the importance of treating specific clinical features. The implementation of this approach within resource constraints is still uncertain.
Article
Clinical Neurology
Xiaoshu Cao, Cristina de Oliveira Francisco, T. Douglas Bradley, Nasim Montazeri Ghahjaverestan, Susan M. Tarlo, Matthew B. Stanbrook, Kenneth R. Chapman, Mark Inman, Azadeh Yadollahi
Summary: Patients with asthma and co-existing OSA have a higher prevalence of obstructive sleep apnea, with increased thoracic fluid volume and small airways narrowing compared to those without OSA.
NATURE AND SCIENCE OF SLEEP
(2022)
Review
Medicine, General & Internal
Omar S. Usmani, Rajiv Dhand, Federico Lavorini, David Price
Summary: Small airways disease is a key feature of COPD and can have significant clinical consequences if left untreated. Early detection of small airways disease remains a major challenge, and research on new drugs and treatments is needed to improve management of the condition.
MAYO CLINIC PROCEEDINGS
(2021)